{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:00:02Z","timestamp":1740124802932,"version":"3.37.3"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"11-12","license":[{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100010035","name":"Outstanding Youth Foundation of Jiangsu Province of China","doi-asserted-by":"publisher","award":["BK20210903","BK20210903"],"award-info":[{"award-number":["BK20210903","BK20210903"]}],"id":[{"id":"10.13039\/501100010035","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1038\/s41434-024-00492-8","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T16:02:04Z","timestamp":1728489724000},"page":"614-624","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting serum response factor (SRF) deactivates \u0394FosB and mitigates Levodopa-induced dyskinesia in a mouse model of Parkinson\u2019s disease"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2436-0943","authenticated-orcid":false,"given":"Piniel Alphayo","family":"Kambey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"WenYa","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingyu","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wokuheleza","family":"Buberwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanxi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,9]]},"reference":[{"key":"492_CR1","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00702-018-1900-6","volume":"125","author":"TN Tran","year":"2018","unstructured":"Tran TN, Vo TNN, Frei K, Truong DD. Levodopa-induced dyskinesia: clinical features, incidence, and risk factors. J Neural Transm (Vienna). 2018;125:1109\u201317.","journal-title":"J Neural Transm (Vienna)"},{"key":"492_CR2","doi-asserted-by":"crossref","unstructured":"di Biase L, Pecoraro PM, Carbone SP, Caminiti ML, Di Lazzaro V. Levodopa-induced dyskinesias in Parkinson\u2019s disease: an overview on pathophysiology, clinical manifestations, therapy management strategies and future directions. J Clin Med. 2023;12:4427.","DOI":"10.3390\/jcm12134427"},{"key":"492_CR3","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.4103\/1673-5374.373710","volume":"18","author":"B Xiao","year":"2023","unstructured":"Xiao B, Tan EK. Cell replacement for Parkinson\u2019s disease: advances and challenges. Neural Regen Res. 2023;18:2693\u20134.","journal-title":"Neural Regen Res"},{"key":"492_CR4","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/35086062","volume":"2","author":"E Bezard","year":"2001","unstructured":"Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci. 2001;2:577\u201388.","journal-title":"Nat Rev Neurosci"},{"key":"492_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41531-018-0069-x","volume":"4","author":"P Eusebi","year":"2018","unstructured":"Eusebi P, Romoli M, Paoletti FP, Tambasco N, Calabresi P, Parnetti L. Risk factors of levodopa-induced dyskinesia in Parkinson\u2019s disease: results from the PPMI cohort. NPJ Parkinsons Dis. 2018;4:33.","journal-title":"NPJ Parkinsons Dis"},{"key":"492_CR6","doi-asserted-by":"publisher","first-page":"7335","DOI":"10.1523\/JNEUROSCI.0252-10.2010","volume":"30","author":"X Cao","year":"2010","unstructured":"Cao X, Yasuda T, Uthayathas S, Watts RL, Mouradian MM, Mochizuki H, et al. Striatal overexpression of DeltaFosB reproduces chronic levodopa-induced involuntary movements. J Neurosci. 2010;30:7335\u201343.","journal-title":"J Neurosci"},{"key":"492_CR7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S0006-8993(02)03289-4","volume":"955","author":"P Svenningsson","year":"2002","unstructured":"Svenningsson P, Arts J, Gunne L, Andren PE. Acute and repeated treatment with L-DOPA increase c-jun expression in the 6-hydroxydopamine-lesioned forebrain of rats and common marmosets. Brain Res. 2002;955:8\u201315.","journal-title":"Brain Res"},{"key":"492_CR8","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.biopsych.2005.05.044","volume":"59","author":"N Pavon","year":"2006","unstructured":"Pavon N, Martin AB, Mendialdua A, Moratalla R. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol Psychiatry. 2006;59:64\u201374.","journal-title":"Biol Psychiatry"},{"key":"492_CR9","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s12640-018-9993-0","volume":"35","author":"V Palafox-Sanchez","year":"2019","unstructured":"Palafox-Sanchez V, Sosti V, Ramirez-Garcia G, Kulisevsky J, Aguilera J, Limon ID. Differential expression of striatal DeltaFosB mRNA and FosB mRNA after different levodopa treatment regimens in a rat model of Parkinson\u2019s disease. Neurotox Res. 2019;35:563\u201374.","journal-title":"Neurotox Res"},{"key":"492_CR10","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1359\/jbmr.080110","volume":"23","author":"G Sabatakos","year":"2008","unstructured":"Sabatakos G, Rowe GC, Kveiborg M, Wu M, Neff L, Chiusaroli R, et al. Doubly truncated FosB isoform (Delta2DeltaFosB) induces osteosclerosis in transgenic mice and modulates expression and phosphorylation of Smads in osteoblasts independent of intrinsic AP-1 activity. J Bone Min Res. 2008;23:584\u201395.","journal-title":"J Bone Min Res"},{"key":"492_CR11","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1021\/acschemneuro.1c00723","volume":"13","author":"AJ Robison","year":"2022","unstructured":"Robison AJ, Nestler EJ. DeltaFOSB: a potentially druggable master orchestrator of activity-dependent gene expression. ACS Chem Neurosci. 2022;13:296\u2013307.","journal-title":"ACS Chem Neurosci"},{"key":"492_CR12","doi-asserted-by":"publisher","first-page":"4933","DOI":"10.1523\/JNEUROSCI.17-13-04933.1997","volume":"17","author":"J Chen","year":"1997","unstructured":"Chen J, Kelz MB, Hope BT, Nakabeppu Y, Nestler EJ. Chronic Fos-related antigens: stable variants of deltaFosB induced in brain by chronic treatments. J Neurosci. 1997;17:4933\u201341.","journal-title":"J Neurosci"},{"key":"492_CR13","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ejphar.2014.10.034","volume":"753","author":"EJ Nestler","year":"2015","unstructured":"Nestler EJ. \u2206FosB: a transcriptional regulator of stress and antidepressant responses. Eur J Pharm. 2015;753:66\u201372.","journal-title":"Eur J Pharm"},{"key":"492_CR14","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/s41434-021-00249-7","volume":"28","author":"G Beck","year":"2021","unstructured":"Beck G, Zhang J, Fong K, Mochizuki H, Mouradian MM, Papa SM. Striatal DeltaFosB gene suppression inhibits the development of abnormal involuntary movements induced by L-Dopa in rats. Gene Ther. 2021;28:760\u201370.","journal-title":"Gene Ther"},{"key":"492_CR15","doi-asserted-by":"publisher","first-page":"18664","DOI":"10.1073\/pnas.1907810116","volume":"116","author":"G Beck","year":"2019","unstructured":"Beck G, Singh A, Zhang J, Potts LF, Woo JM, Park ES, et al. Role of striatal DeltaFosB in l-Dopa-induced dyskinesias of parkinsonian nonhuman primates. Proc Natl Acad Sci USA. 2019;116:18664\u201372.","journal-title":"Proc Natl Acad Sci USA"},{"key":"492_CR16","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.biopsych.2014.07.007","volume":"79","author":"M Engeln","year":"2016","unstructured":"Engeln M, Bastide MF, Toulme E, Dehay B, Bourdenx M, Doudnikoff E, et al. Selective inactivation of striatal FosB\/DeltaFosB-expressing neurons alleviates L-DOPA-induced dyskinesia. Biol Psychiatry. 2016;79:354\u201361.","journal-title":"Biol Psychiatry"},{"key":"492_CR17","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nrn2471","volume":"9","author":"P Jenner","year":"2008","unstructured":"Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci. 2008;9:665\u201377.","journal-title":"Nat Rev Neurosci"},{"key":"492_CR18","first-page":"2037","volume":"18","author":"PA Kambey","year":"2023","unstructured":"Kambey PA, Liu WY, Wu J, Bosco B, Nadeem I, Kanwore K, et al. Single-nuclei RNA sequencing uncovers heterogenous transcriptional signatures in Parkinson\u2019s disease associated with nuclear receptor-related factor 1 defect. Neural Regen Res. 2023;18:2037\u201346.","journal-title":"Neural Regen Res"},{"key":"492_CR19","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1111\/cns.14229","volume":"29","author":"PA Kambey","year":"2023","unstructured":"Kambey PA, Liu WY, Wu J, Tang C, Buberwa W, Saro A, et al. Amphiregulin blockade decreases the levodopa-induced dyskinesia in a 6-hydroxydopamine Parkinson\u2019s disease mouse model. CNS Neurosci Ther. 2023;29:2925\u201339.","journal-title":"CNS Neurosci Ther"},{"key":"492_CR20","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s11011-021-00670-2","volume":"36","author":"PA Kambey","year":"2021","unstructured":"Kambey PA, Chengcheng M, Xiaoxiao G, Abdulrahman AA, Kanwore K, Nadeem I, et al. The orphan nuclear receptor Nurr1 agonist amodiaquine mediates neuroprotective effects in 6-OHDA Parkinson\u2019s disease animal model by enhancing the phosphorylation of P38 mitogen-activated kinase but not PI3K\/AKT signaling pathway. Metab Brain Dis. 2021;36:609\u201325.","journal-title":"Metab Brain Dis"},{"key":"492_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.brainresbull.2004.10.011","volume":"68","author":"C Monville","year":"2005","unstructured":"Monville C, Torres EM, Dunnett SB. Validation of the l-dopa-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists. Brain Res Bull. 2005;68:16\u201323.","journal-title":"Brain Res Bull"},{"key":"492_CR22","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.bbr.2007.01.013","volume":"179","author":"A Dekundy","year":"2007","unstructured":"Dekundy A, Lundblad M, Danysz W, Cenci MA. Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav Brain Res. 2007;179:76\u201389.","journal-title":"Behav Brain Res"},{"key":"492_CR23","doi-asserted-by":"publisher","first-page":"e13861","DOI":"10.1371\/journal.pone.0013861","volume":"5","author":"I Cantuti-Castelvetri","year":"2010","unstructured":"Cantuti-Castelvetri I, Hernandez LF, Keller-McGandy CE, Kett LR, Landy A, Hollingsworth ZR, et al. Levodopa-induced dyskinesia is associated with increased thyrotropin releasing hormone in the dorsal striatum of hemi-parkinsonian rats. PLoS One. 2010;5:e13861.","journal-title":"PLoS One"},{"key":"492_CR24","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11010-019-03592-x","volume":"461","author":"JL Zhu","year":"2019","unstructured":"Zhu JL, Wu YY, Wu D, Luo WF, Zhang ZQ, Liu CF. SC79, a novel Akt activator, protects dopaminergic neuronal cells from MPP(+) and rotenone. Mol Cell Biochem. 2019;461:81\u20139.","journal-title":"Mol Cell Biochem"},{"key":"492_CR25","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1038\/s41418-019-0299-4","volume":"26","author":"Y Li","year":"2019","unstructured":"Li Y, Feng D, Wang Z, Zhao Y, Sun R, Tian D, et al. Ischemia-induced ACSL4 activation contributes to ferroptosis-mediated tissue injury in intestinal ischemia\/reperfusion. Cell Death Differ. 2019;26:2284\u201399.","journal-title":"Cell Death Differ"},{"key":"492_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2022.104846","volume":"129","author":"A Goyal","year":"2023","unstructured":"Goyal A, Agrawal A, Verma A, Dubey N. The PI3K-AKT pathway: a plausible therapeutic target in Parkinson\u2019s disease. Exp Mol Pathol. 2023;129:104846.","journal-title":"Exp Mol Pathol"},{"key":"492_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.648636","volume":"12","author":"HZ Long","year":"2021","unstructured":"Long HZ, Cheng Y, Zhou ZW, Luo HY, Wen DD, Gao LC. PI3K\/AKT signal pathway: a target of natural products in the prevention and treatment of Alzheimer\u2019s disease and Parkinson\u2019s disease. Front Pharm. 2021;12:648636.","journal-title":"Front Pharm"},{"key":"492_CR28","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41531-020-0110-8","volume":"6","author":"J Tran","year":"2020","unstructured":"Tran J, Anastacio H, Bardy C. Genetic predispositions of Parkinson\u2019s disease revealed in patient-derived brain cells. NPJ Parkinsons Dis. 2020;6:8.","journal-title":"NPJ Parkinsons Dis"},{"key":"492_CR29","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1038\/466S6a","volume":"466","author":"A Abbott","year":"2010","unstructured":"Abbott A. Levodopa: the story so far. Nature. 2010;466:S6\u20137.","journal-title":"Nature"},{"key":"492_CR30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/226021a0","volume":"226","author":"DB Calne","year":"1970","unstructured":"Calne DB, Sandler M. L-Dopa and Parkinsonism. Nature. 1970;226:21\u20134.","journal-title":"Nature"},{"key":"492_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-04356-8","volume":"12","author":"LL Raket","year":"2022","unstructured":"Raket LL, Oudin Astrom D, Norlin JM, Kellerborg K, Martinez-Martin P, Odin P. Impact of age at onset on symptom profiles, treatment characteristics and health-related quality of life in Parkinson\u2019s disease. Sci Rep. 2022;12:526.","journal-title":"Sci Rep."},{"key":"492_CR32","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/72929","volume":"3","author":"O Aizman","year":"2000","unstructured":"Aizman O, Brismar H, Uhlen P, Zettergren E, Levey AI, Forssberg H, et al. Anatomical and physiological evidence for D1 and D2 dopamine receptor colocalization in neostriatal neurons. Nat Neurosci. 2000;3:226\u201330.","journal-title":"Nat Neurosci"},{"key":"492_CR33","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1152\/jn.00481.2019","volume":"122","author":"M Filipovic","year":"2019","unstructured":"Filipovic M, Ketzef M, Reig R, Aertsen A, Silberberg G, Kumar A. Direct pathway neurons in mouse dorsolateral striatum in vivo receive stronger synaptic input than indirect pathway neurons. J Neurophysiol. 2019;122:2294\u2013303.","journal-title":"J Neurophysiol"},{"key":"492_CR34","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/sj.cdd.4401648","volume":"12","author":"H Kurushima","year":"2005","unstructured":"Kurushima H, Ohno M, Miura T, Nakamura TY, Horie H, Kadoya T, et al. Selective induction of DeltaFosB in the brain after transient forebrain ischemia accompanied by an increased expression of galectin-1, and the implication of DeltaFosB and galectin-1 in neuroprotection and neurogenesis. Cell Death Differ. 2005;12:1078\u201396.","journal-title":"Cell Death Differ"},{"key":"492_CR35","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1016\/j.ejca.2005.08.008","volume":"41","author":"K Milde-Langosch","year":"2005","unstructured":"Milde-Langosch K. The Fos family of transcription factors and their role in tumourigenesis. Eur J Cancer. 2005;41:2449\u201361.","journal-title":"Eur J Cancer"},{"key":"492_CR36","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.molcel.2016.10.016","volume":"64","author":"F Gualdrini","year":"2016","unstructured":"Gualdrini F, Esnault C, Horswell S, Stewart A, Matthews N, Treisman R. SRF Co-factors Control the Balance between Cell Proliferation and Contractility. Mol Cell. 2016;64:1048\u201361.","journal-title":"Mol Cell"},{"key":"492_CR37","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1111\/febs.15544","volume":"288","author":"JO Onuh","year":"2021","unstructured":"Onuh JO, Qiu H. Serum response factor-cofactor interactions and their implications in disease. FEBS J. 2021;288:3120\u201334.","journal-title":"FEBS J"},{"key":"492_CR38","first-page":"147","volume":"53","author":"J Chai","year":"2002","unstructured":"Chai J, Tarnawski AS. Serum response factor: discovery, biochemistry, biological roles and implications for tissue injury healing. J Physiol Pharm. 2002;53:147\u201357.","journal-title":"J Physiol Pharm"},{"key":"492_CR39","doi-asserted-by":"crossref","unstructured":"Song J, Dikwella N, Sinske D, Roselli F, Knoll B. SRF deletion results in earlier disease onset in a mouse model of amyotrophic lateral sclerosis. JCI Insight. 2023;8:e167694.","DOI":"10.1172\/jci.insight.167694"},{"key":"492_CR40","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.neuroscience.2017.11.040","volume":"371","author":"XY Cheng","year":"2018","unstructured":"Cheng XY, Li SY, Mao CJ, Wang MX, Chen J, Wang F, et al. Serum response factor promotes dopaminergic neuron survival via activation of beclin 1-dependent autophagy. Neuroscience. 2018;371:288\u201395.","journal-title":"Neuroscience"},{"key":"492_CR41","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1073\/pnas.0608251104","volume":"104","author":"N Chow","year":"2007","unstructured":"Chow N, Bell RD, Deane R, Streb JW, Chen J, Brooks A, et al. Serum response factor and myocardin mediate arterial hypercontractility and cerebral blood flow dysregulation in Alzheimer\u2019s phenotype. Proc Natl Acad Sci USA. 2007;104:823\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"492_CR42","doi-asserted-by":"publisher","first-page":"4549","DOI":"10.1007\/s12035-020-02041-x","volume":"57","author":"L Vidal-Sancho","year":"2020","unstructured":"Vidal-Sancho L, Fernandez-Garcia S, Soles-Tarres I, Alberch J, Xifro X. Decreased myocyte enhancer factor 2 levels in the hippocampus of Huntington\u2019s disease mice are related to cognitive dysfunction. Mol Neurobiol. 2020;57:4549\u201362.","journal-title":"Mol Neurobiol"},{"key":"492_CR43","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1096\/fj.09-151423","volume":"24","author":"JR Parkitna","year":"2010","unstructured":"Parkitna JR, Bilbao A, Rieker C, Engblom D, Piechota M, Nordheim A, et al. Loss of the serum response factor in the dopamine system leads to hyperactivity. FASEB J. 2010;24:2427\u201335.","journal-title":"FASEB J"},{"key":"492_CR44","doi-asserted-by":"publisher","first-page":"63","DOI":"10.4103\/CJP.CJP_1_19","volume":"62","author":"SP Yang","year":"2019","unstructured":"Yang SP, Lo CY, Tseng HM, Chao CC. Knockdown of protein kinase CK2 blocked gene expression mediated by brain-derived neurotrophic factor-induced serum response element. Chin J Physiol. 2019;62:63\u20139.","journal-title":"Chin J Physiol"},{"key":"492_CR45","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s12035-019-01720-8","volume":"57","author":"L Gerosa","year":"2020","unstructured":"Gerosa L, Grillo B, Forastieri C, Longaretti A, Toffolo E, Mallei A, et al. SRF and SRFDelta5 splicing isoform recruit corepressor LSD1\/KDM1A modifying structural neuroplasticity and environmental stress response. Mol Neurobiol. 2020;57:393\u2013407.","journal-title":"Mol Neurobiol"},{"key":"492_CR46","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.biopsych.2006.11.032","volume":"62","author":"JE Westin","year":"2007","unstructured":"Westin JE, Vercammen L, Strome EM, Konradi C, Cenci MA. Spatiotemporal pattern of striatal ERK1\/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol Psychiatry. 2007;62:800\u201310.","journal-title":"Biol Psychiatry"},{"key":"492_CR47","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1111\/j.1471-4159.2008.05831.x","volume":"108","author":"E Santini","year":"2009","unstructured":"Santini E, Alcacer C, Cacciatore S, Heiman M, Herve D, Greengard P, et al. L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice. J Neurochem. 2009;108:621\u201333.","journal-title":"J Neurochem"},{"key":"492_CR48","doi-asserted-by":"publisher","first-page":"21824","DOI":"10.1073\/pnas.1012071107","volume":"107","author":"S Fasano","year":"2010","unstructured":"Fasano S, Bezard E, D\u2019Antoni A, Francardo V, Indrigo M, Qin L, et al. Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia. Proc Natl Acad Sci USA. 2010;107:21824\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"492_CR49","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.4161\/cbt.12.12.18442","volume":"12","author":"SV Madhunapantula","year":"2011","unstructured":"Madhunapantula SV, Mosca PJ, Robertson GP. The Akt signaling pathway: an emerging therapeutic target in malignant melanoma. Cancer Biol Ther. 2011;12:1032\u201349.","journal-title":"Cancer Biol Ther"},{"key":"492_CR50","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.7150\/ijbs.27173","volume":"14","author":"X Huang","year":"2018","unstructured":"Huang X, Liu G, Guo J, Su Z. The PI3K\/AKT pathway in obesity and type 2 diabetes. Int J Biol Sci. 2018;14:1483\u201396.","journal-title":"Int J Biol Sci"},{"key":"492_CR51","first-page":"6260","volume":"13","author":"VM Rivera","year":"1993","unstructured":"Rivera VM, Miranti CK, Misra RP, Ginty DD, Chen RH, Blenis J, et al. A growth factor-induced kinase phosphorylates the serum response factor at a site that regulates its DNA-binding activity. Mol Cell Biol. 1993;13:6260\u201373.","journal-title":"Mol Cell Biol"},{"key":"492_CR52","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1073\/pnas.1000300107","volume":"107","author":"EM Small","year":"2010","unstructured":"Small EM, O\u2019Rourke JR, Moresi V, Sutherland LB, McAnally J, Gerard RD, et al. Regulation of PI3-kinase\/Akt signaling by muscle-enriched microRNA-486. Proc Natl Acad Sci USA. 2010;107:4218\u201323.","journal-title":"Proc Natl Acad Sci USA"},{"key":"492_CR53","doi-asserted-by":"publisher","first-page":"4955","DOI":"10.1093\/emboj\/19.18.4955","volume":"19","author":"S Poser","year":"2000","unstructured":"Poser S, Impey S, Trinh K, Xia Z, Storm DR. SRF-dependent gene expression is required for PI3-kinase-regulated cell proliferation. EMBO J. 2000;19:4955\u201366.","journal-title":"EMBO J"},{"key":"492_CR54","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.bbadis.2009.12.009","volume":"1802","author":"EK Kim","year":"2010","unstructured":"Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta. 2010;1802:396\u2013405.","journal-title":"Biochim Biophys Acta"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-024-00492-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-024-00492-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-024-00492-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T02:06:09Z","timestamp":1732068369000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-024-00492-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,9]]},"references-count":54,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["492"],"URL":"https:\/\/doi.org\/10.1038\/s41434-024-00492-8","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"type":"print","value":"0969-7128"},{"type":"electronic","value":"1476-5462"}],"subject":[],"published":{"date-parts":[[2024,10,9]]},"assertion":[{"value":"17 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Laboratory animal care and use protocols approved by the Xuzhou Medical University\u2019s institutional animal care and use committee. This study exclusively utilized mice, therefore consent to participate is not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent to the publication of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}